Others

Items 7551-7600 of 13502

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. Drug Impurity

    Dacomitinib impurity 3 is a known impurity associated with the tyrosine kinase inhibitor Dacomitinib. This compound can be utilized in analytical studies to evaluate the purity and stability of pharmaceutical formulations containing Dacomitinib. Its characterization is essential for ensuring the quality and compliance of drug products in the development process.
  2. Drug Impurity

    Clopidogrel impurity 3 is a known impurity associated with Clopidogrel, a popular antiplatelet medication. This compound serves as an important analytical reference in the assessment of drug purity and quality control. Its characterization is essential for the evaluation of formulation stability and potential pharmacological effects during research and development.
  3. Drug Impurity

    Ticagrelor impurity 22 is a known impurity associated with Ticagrelor, a potent P2Y12 platelet receptor inhibitor. This compound is utilized in the characterization of drug formulations and is critical for ensuring the quality and safety of pharmaceutical products. Its study is essential for regulatory compliance and may assist in understanding the stability and degradation pathways of Ticagrelor-based therapies.
  4. Drug Intermediate

    Cyanoacetohydrazide serves as a pharmaceutical intermediate, primarily utilized in the synthesis of acylhydrazide hydrazone derivatives. These derivatives have demonstrated notable antibacterial and anti-tumor activities, making cyanoacetohydrazide a valuable compound in drug development and medicinal chemistry research. Its versatile applications in synthesizing bioactive compounds contribute significantly to advancing therapeutic strategies.
  5. Drug Intermediate

    3-(4-Chlorophenoxy)-4-methylaniline serves as a critical drug intermediate utilized in the synthesis of a range of active pharmaceutical ingredients. This compound is integral in the development of various therapeutic agents, enabling effective chemical transformations in medicinal chemistry. Its unique structural features allow for versatile applications in pharmaceutical research and development.
  6. Drug Impurity

    Omeprazole impurity 13 is a chemical impurity associated with the proton pump inhibitor omeprazole. It is utilized primarily in drug quality control and stability studies to ensure the purity of omeprazole formulations. The characterization of this impurity is crucial for regulatory compliance and assessing the safety and efficacy of pharmaceutical products containing omeprazole.
  7. Biochemical Reagent

    Drotaveraldine is a biochemical reagent that participates in domino reactions with α,β-unsaturated aldehydes. Through these reactions, it enables the synthesis of pyrrolo[2,1-a]isoquinolines, which are valuable intermediates in chemical research. This compound is utilized in studies focused on organic synthesis and the development of novel biochemical pathways.
  8. Drug Impurity

    2-Hydroxy-3-nitrobenzaldehyde is characterized as a drug impurity, primarily affecting the purity profile of pharmaceutical compounds. This compound serves as an important reference standard in analytical chemistry, utilized in the assessment of drug formulations and in quality control processes. Its presence can impact pharmacokinetics and safety evaluations, making it relevant for research focusing on drug development and regulatory compliance.
  9. Drug Impurity

    Vitamin Impurity 2 is a known impurity associated with Vitamin compounds. It serves as a critical reference standard in pharmaceutical research and development to evaluate the purity and quality of Vitamin formulations. Its identification and quantification are essential for ensuring compliance with regulatory standards in drug manufacturing.
  10. Drug Intermediate

    2,3,4-Tri-O-acetyl-β-D-glucuronide methyl ester is a synthetic intermediate utilized in the preparation of prodrug forms of the antitumor antibiotic Daunomycin. This compound exhibits crucial functionalities in glycosylation reactions, facilitating drug development and optimization. Its applications in medicinal chemistry and pharmaceutical research make it a valuable reagent for advancing therapeutic formulations in oncology research.
  11. Drug Intermediate

    42-O-(2-Azidoethyl)-Rapamycin is an azide-modified derivative of Rapamycin, functioning as an important drug intermediate for synthetic applications. It facilitates the development of Rapamycin derivatives, which are of interest in various therapeutic contexts, particularly in cancer research and immunosuppression studies. This compound's unique structure allows for further modifications that can enhance biological activity and specificity in target engagement.
  12. Drug Intermediate

    Methyl (3S,6R)-6-methyl-3-piperidinecarboxylate L-tartaric acid salt serves as a versatile drug intermediate in the synthesis of various bioactive compounds. This compound plays a crucial role in the preparation of pharmaceutical agents, contributing to diverse chemical structures and medicinal properties. Its application is significant in the fields of medicinal chemistry and drug development.
  13. Drug Impurity

    Sunitinib impurity 28 is a recognized impurity associated with Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor. It serves as a critical reference standard in the analysis of Sunitinib and is pivotal for assessing drug purity and stability in pharmaceutical formulations. This impurity is essential for quality control and research applications focused on the metabolism and pharmacokinetics of Sunitinib.
  14. Drug Impurity

    Afatinib impurity 34 is a known impurity associated with the drug Afatinib, an irreversible ErbB receptor tyrosine kinase inhibitor. This compound is primarily utilized for quality control and analytical studies in pharmaceutical development to ensure the purity and compliance of Afatinib formulations. Its characterization is essential for understanding the potential impact of impurities on drug efficacy and safety profiles.
  15. Drug Intermediate

    6,7-Dibromoquinoline-5,8-dione is a versatile drug intermediate utilized in the synthesis of a variety of biologically active compounds. This compound serves as a crucial building block in medicinal chemistry and pharmaceutical development, facilitating the creation of novel therapeutic agents. Its incorporation into chemical reactions can lead to the development of compounds with potential applications in diverse areas of drug discovery and development.
  16. Drug Impurity

    Methyl 3-chlorobenzoate is a compound commonly categorized as a drug impurity. It is utilized in chemical research to study the implications of impurities in drug development processes. This reagent serves as a valuable tool for evaluating the stability and efficacy of pharmaceutical formulations.
  17. Drug Impurity

    Rosuvastatin impurity 46, also known as Rosuvastatin ethyl ester, is a chemical impurity associated with the cholesterol-lowering drug Rosuvastatin. It is utilized primarily in drug development and quality control processes to assess the purity of Rosuvastatin formulations. This reagent aids researchers in understanding the metabolic pathways and potential impacts of drug impurities on pharmacokinetics and safety profiles.
  18. Drug Impurity

    Rosuvastatin impurity 10, also known as 5-Oxo rosuvastatin, is a recognized impurity of Rosuvastatin. This compound serves as a reference standard in the assessment and quality control of Rosuvastatin formulations. Its characterization is essential for ensuring drug purity and compliance with regulatory standards in pharmaceutical research and development.
  19. Drug Impurity

    Rivaroxaban impurity 47 is a chemical impurity associated with the anticoagulant Rivaroxaban, which directly targets factor Xa in the coagulation cascade. This compound serves as a crucial reference standard for quality control and stability testing in pharmaceutical research. Its characterization is essential for evaluating the purity of Rivaroxaban formulations during drug development and regulatory assessments.
  20. Drug Intermediate

    Triphenylene is a highly symmetrical polycyclic aromatic hydrocarbon that serves as a valuable drug intermediate. It facilitates the synthesis of triphenyl polycyclic aromatic hydrocarbons (PAHs), which are significant in various chemical applications. Notably, Triphenylene demonstrates no carcinogenic activity in mouse skin application experiments, supporting its use in safe pharmaceutical development and research.
  21. Drug Intermediate

    4-Methylbenzothioamide is a cyclic thioamide used as a building block in drug discovery chemistry. This compound serves as an important intermediate in the synthesis of various pharmaceutical agents. Its unique structure allows for the modification of bioactive molecules, facilitating the development of novel therapeutics.
  22. Impurity reference

    Rabeprazole sulfone is a metabolite of the proton pump inhibitor Rabeprazole, serving as an impurity reference in pharmaceutical research. This compound is essential for quality control and analytical studies that require the assessment of Rabeprazole's purity. Its identification and quantification support the development of reliable therapeutic formulations and ensure compliance with regulatory standards.
  23. Drug Impurity

    trans-4-[Bis(phenylmethyl)amino]cyclohexanecarboxylic acid functions primarily as a drug impurity. It is relevant in pharmaceutical research, particularly in the assessment of drug purity and the investigation of potential contaminants. This compound aids in understanding the implications of impurities in drug formulation and safety profiles.
  24. Drug Impurity

    Dexamethasone impurity 3 is a known impurity of Dexamethasone, a synthetic glucocorticoid. This compound is relevant in pharmaceutical research and quality control, as it is necessary for assessing the purity and stability of Dexamethasone formulations. Understanding the presence and behavior of this impurity can facilitate the development of more effective and consistent glucocorticoid therapies.
  25. Drug Intermediate

    N,N-Dimethyl-L-valine is a synthetic amino acid derivative commonly used as a drug intermediate in pharmaceutical synthesis. This compound serves as a valuable building block in the development of various bioactive molecules, facilitating the creation of novel therapeutic agents. Its structural properties contribute to the modulation of biological activity, making it an essential reagent in chemical research and drug discovery applications.
  26. Drug Intermediate

    tert-Butyl chlorosulfonylcarbamate compound with 1,4-diazabicyclo[2.2.2]octane (1:2) serves as a versatile drug intermediate, facilitating the synthesis of a range of bioactive molecules. This compound is particularly useful in the development of pharmaceuticals due to its ability to participate in multistep synthesis reactions, enhancing chemical pathways for novel drug discovery and development. Its unique structure enables precise functionalization, making it an essential reagent in chemical research and medicinal chemistry applications.
  27. Drug Impurity

    Ticagrelor impurity 12 is identified as a chemical impurity associated with Ticagrelor, an antiplatelet medication. This compound is critical for analytical studies focusing on the purification and identification of drug metabolites. Its characterization is essential for ensuring the safety and efficacy of Ticagrelor in pharmaceutical research and quality control processes.
  28. Drug Impurity

    Cinacalcet impurity 6 is a known impurity related to the active pharmaceutical ingredient Cinacalcet, which acts as a calcimimetic agent targeting the calcium-sensing receptor. This compound is utilized primarily in the assessment of drug purity and quality control in pharmaceutical development. Proper identification and quantification of this impurity are essential for ensuring the safety and efficacy of drug formulations containing Cinacalcet.
  29. Drug Impurity

    Ticagrelor impurity 26 is a known impurity associated with the antiplatelet agent Ticagrelor, primarily targeting the P2Y12 receptor. This compound is crucial for the study of drug purity and quality control in pharmaceutical development. It aids researchers in understanding the implications of impurities on drug efficacy and safety, making it an essential tool for analytical and formulation studies in the pharmaceutical industry.
  30. Drug Impurity

    Sildenafil impurity 17 is a defined impurity associated with the synthesis of Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor. This compound is important for assessing the purity of pharmaceutical formulations and plays a critical role in quality control during drug development. Researchers can utilize Sildenafil impurity 17 to ensure compliance with regulatory standards and investigate its impact on the efficacy and safety profiles of Sildenafil-based therapies.
  31. Drug Intermediate

    2,2-Dibenzyl-1,3-propanediol serves as a crucial drug intermediate in the synthesis of various pharmacologically active compounds. It contributes to the formation of complex molecular structures, facilitating the development of new therapeutics. This compound is valuable in medicinal chemistry and drug development applications, where it supports the exploration of innovative treatments.
  32. Drug Intermediate

    Methyl 9H-xanthene-9-carboxylate serves as a crucial intermediate in the synthesis of diverse active pharmaceutical compounds. This compound plays an essential role in the development of xanthene derivatives, which are of significant interest in chemical and medicinal research. Its utility in drug synthesis supports studies aimed at optimizing pharmacological properties and biological activities.
  33. Drug Intermediate

    4-Chlorophenyl-2-pyridinylmethanol is a versatile synthetic intermediate primarily utilized in pharmaceutical synthesis. This compound acts as a building block in the development of various bioactive molecules, facilitating the production of targeted therapeutics. Its efficacy in chemical reactions makes it a valuable reagent for researchers engaged in drug discovery and development.
  34. Drug Impurity

    Anastrozole impurity 1 is a known impurity derived from the aromatase inhibitor Anastrozole, primarily targeting estrogen synthesis. This compound is critical for analytical chemistry and quality control in the pharmaceutical industry, serving as a reference standard for the identification and quantification of impurities in formulations containing Anastrozole. Researchers utilize it to ensure the purity and safety of drug products in compliance with regulatory standards.
  35. Drug Impurity

    Ticagrelor impurity 7 is a known impurity associated with the antiplatelet agent Ticagrelor. This compound serves as a reference standard for the analysis and quality control of Ticagrelor in pharmaceutical formulations. Its identification is critical for ensuring the consistency and safety of Ticagrelor-based therapies in drug development and research applications.
  36. Drug Impurity

    Rebamipide impurity 13 is a recognized impurity associated with Rebamipide, a drug primarily used for its gastroprotective properties. This compound serves as a valuable reference standard in the analysis and quality control of pharmaceutical formulations containing Rebamipide. Its presence may influence the pharmacological profile and therapeutic efficacy, making it essential for research applications focused on drug development and safety assessment.
  37. Drug Impurity

    Voriconazole impurity 1 is a recognized impurity of the antifungal agent Voriconazole, which targets fungal cytochromes P450 to inhibit ergosterol synthesis. This compound is utilized in the evaluation of pharmaceutical purity and stability studies, as well as in toxicological assessments. Its presence can impact the safety profile and efficacy of Voriconazole in clinical applications.
  38. Drug Impurity

    Nintedanib Impurity 10 is a chemical impurity associated with Nintedanib, a targeted therapy for various fibrotic diseases. This compound serves as a reference standard for the analytical assessment of Nintedanib formulations, ensuring the quality and consistency of pharmaceutical preparations. Its presence is critical for quality control and regulatory compliance in drug development processes.
  39. Drug Impurity

    Mivacurium chloride impurity 6 is a known impurity associated with the neuromuscular blocker Mivacurium chloride. It serves as a critical reference compound for quality assurance and method validation in pharmaceutical development. This impurity can be utilized in analytical studies to assess the purity of Mivacurium chloride formulations and to understand potential effects on safety and efficacy in drug manufacturing processes.
  40. Drug Intermediate Control

    2-Pyrimidinepropanoic acid is a synthetic intermediate primarily utilized in pharmaceutical synthesis. This compound serves as a key building block in the development of various bioactive molecules and drug candidates, facilitating research in medicinal chemistry. Its role in the modification of bioactive compounds makes it valuable for applications in drug discovery and development.
  41. MRX-I Prodrug Intermediate

    Contezolid phosphoramidic acid is a key intermediate in the synthesis of MRX-I, an antibacterial oxazolidinone agent. This compound plays a critical role in the development of proagents designed to combat bacterial infections. Its relevance in medicinal chemistry makes it an essential reagent for research applications focused on antibiotic efficacy and development.
  42. Drug Intermediate

    5-Ethoxy-4-methyloxazole is a chemical intermediate primarily utilized in the synthesis of pharmaceutical compounds. This heterocyclic compound contributes to the development of various drug candidates by serving as a building block in organic synthesis. Its structural characteristics support research in medicinal chemistry and the design of novel therapeutics.
  43. Drug Intermediate

    tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate serves as an important intermediate in the synthesis of potent DP2 receptor antagonists derived from a novel spiro-indolinone framework. This compound is significant for its role in drug discovery, particularly in the development of therapeutics aimed at modulating immune responses and inflammation pathways. Researchers utilize this intermediate to facilitate the creation of compounds with potential clinical applications in treating allergic and inflammatory diseases.
  44. Drug Intermediate

    Stemmadenine is a strychnos-type monoterpenoid indole alkaloid that functions as a crucial biosynthetic precursor in the formation of monoterpenoid indole alkaloid structures. Its primary mechanism involves contributing to the synthesis of complex alkaloids, making it valuable in drug development and research into natural product synthesis. Stemmadenine is utilized extensively in studies focused on the biosynthetic pathways of alkaloids and their potential therapeutic applications.
  45. Drug Intermediate

    (2R,3S,4R,5R)-GlcAc-GlcA is a hexose derivative primarily utilized as a drug intermediate in the synthesis of antibody-drug conjugate (ADC) linkers. Its structural features contribute to the development of more effective targeted therapies in oncology research. This compound serves as a valuable building block in the formulation of bioconjugates, enhancing the specificity and efficacy of therapeutic agents.
  46. Drug Intermediate

    2-Phenylacrylonitrile is a versatile pharmaceutical intermediate that serves as a precursor in the synthesis of various compounds. Its derivatives are utilized in cancer research, particularly in the development of cancer therapeutics and mechanisms of action studies. This compound provides essential building blocks for the exploration of anticancer agents and their biological activity.
  47. Drug Intermediate

    Fmoc-PNA-maleimide-OH is a Fmoc-protected peptide nucleic acid monomer that incorporates a maleimide moiety, enabling selective thiol-reactive conjugation. This compound facilitates the construction of peptide nucleic acid (PNA) conjugates, which are valuable in molecular assembly and bioconjugation applications. Its unique functionalization allows for enhanced versatility in the design of nucleic acid-based tools for research and therapeutic development.
  48. Phosphoramidite Compound

    3'-NH-Tr-2',3'-dT-5'-CE-Phosphoramidite is a phosphoramidite compound utilized in the synthesis of oligonucleotides and nucleic acid analogs. It plays a crucial role in the development of antiviral and anticancer research applications. This reagent facilitates the incorporation of modified nucleotides, enabling the exploration of therapeutic strategies in nucleic acid-based interventions.
  49. Drug Intermediate

    Erlotinib lactam impurity is a chemical precursor of the tyrosine kinase inhibitor erlotinib. This compound serves as an important intermediate in the synthesis of anti-cancer therapeutics, particularly in the study of targeted therapies for non-small cell lung cancer. Its role in drug development makes it a valuable reagent for research applications focused on kinase inhibition and related signaling pathways.
  50. Drug Intermediate

    3-(Trimethylsilyl)-1-propanesulfonic acid sodium functions as a drug intermediate, facilitating various chemical reactions. This compound serves as a versatile reagent in the synthesis of peptides, proteins, and nucleic acids. Its efficacy in stabilizing reactive intermediates makes it a valuable tool for researchers in biochemical and pharmaceutical applications.

Items 7551-7600 of 13502

Page
per page
Set Descending Direction